多肽药物口服递送的挑战与新进展  

Challenges and New Developments of Oral Peptide Delivery

作　　者：阮思达 冯军 李雅楠 东圆珍 陆伟根 RUAN Sida;FENG Jun;LI Yanan;DONG Yuanzhen;LU Weigen(China State Institute of Pharmaceutical Industry,Shanghai 201203;School of Pharmacy,Fudan University,Shanghai 201203)

机构地区：[1]中国医药工业研究总院,上海201203 [2]复旦大学药学院,上海201203

出　　处：《中国医药工业杂志》2020年第12期1475-1486,共12页Chinese Journal of Pharmaceuticals

基　　金：国家十三五“重大新药创制”科技重大专项(2018ZX09721003-008-015)。

摘　　要：实现多肽药物的口服利用,一直以来都是人们研究的热点。然而由于胃肠道复杂的生理屏障,口服多肽药物的生物利用度一直较低。本文归纳了阻碍多肽药物口服吸收的主要屏障,并综述了针对不同屏障所采取的相应治疗策略。与此同时,本文还列举了目前应用于多肽药物口服递送的新技术与新进展,这些新技术的发展将会为提高多肽药物口服生物利用度带来新希望。Achieving oral delivery of peptide drugs has drawn a lot of attention in recent years.However,the complex gastrointestinal barriers cause extremely low oral bioavailability.In this review,we summarize the important barriers to oral absorption of peptide drugs as well as different strategies for overcoming the corresponding barriers.At the same time,new technologies and advances in oral delivery of peptide drugs are also presented in this paper,which will bring new hope for improvement in oral bioavailability of peptides.

关 键 词：多肽药物 口服递送 胃肠道屏障 生物利用度 新技术 

分 类 号：R944.9[医药卫生—药剂学]